Cargando…
GP或TP化疗联合热疗治疗非小细胞肺癌的系统评价
BACKGROUND AND OBJECTIVE: Advanced non-small cell lung cancer (NSCLC) is characterized by poor treatment efficacy and short survival time. Clinical trials have shown that the combination of chemotherapy with thermotherapy exhibits strong efficacy. We performed this meta-analysis to evaluate the clin...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999956/ https://www.ncbi.nlm.nih.gov/pubmed/22901992 http://dx.doi.org/10.3779/j.issn.1009-3419.2012.08.02 |
_version_ | 1783331568378445824 |
---|---|
collection | PubMed |
description | BACKGROUND AND OBJECTIVE: Advanced non-small cell lung cancer (NSCLC) is characterized by poor treatment efficacy and short survival time. Clinical trials have shown that the combination of chemotherapy with thermotherapy exhibits strong efficacy. We performed this meta-analysis to evaluate the clinical efficacy and safety of gemcitabine plus cisplatin (GP) and paclitaxel plus cisplatin (TP) combined with thermotherapy in the treatment of NSCLC, as well as to provide reference for clinical practice and future research. METHODS: We searched international (Cochrane Library, PubMed, and EMBASE) and Chinese (CBM, CNKI, VIP and Wanfang) databases for relevant articles and imported other retrievable sources, such as tracing-related references. We also corresponded with other authors to obtain certain inaccessible information. Data from all relevant randomized controlled trials (RCT) were collected to compare GP or TP thermochemotherapy with GP or TP chemotherapy alone. The quality of the included studies was assessed by adequate outcome-based standards and clinical circumstances. The meta-analysis was conducted using RevMan 5.1. RESULTS: Fifteen RCTs involving 952 patients were included in this meta-analysis. The results showed that the thermochemotherapy group had higher rates of improvement in quality of life (OR=3.84, 95%CI: 2.61-5.64), survival at 1 year (HR=1.94, 95%CI: 1.21-3.12), and survival at 2 years (HR=2.05, 95%CI: 1.18-3.58) compared with the chemotherapy group, with the differences between them being significant. However, these groups did not differ in other indicators of treatment effectiveness, such as myelosuppression, alimentary canal reactions, hepatic lesions, and diarrhea. CONCLUSION: Compared with chemotherapy alone, thermochemotherapy can improve survival rates and curative effects, ameliorate symptoms, and enhance the quality of life of patients with advanced NSCLC, and it has an acceptable safety profile. The results of this meta-analysis warrant further investigation with a larger sample size and using a high-quality RCT design. |
format | Online Article Text |
id | pubmed-5999956 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | 中国肺癌杂志编辑部 |
record_format | MEDLINE/PubMed |
spelling | pubmed-59999562018-07-06 GP或TP化疗联合热疗治疗非小细胞肺癌的系统评价 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: Advanced non-small cell lung cancer (NSCLC) is characterized by poor treatment efficacy and short survival time. Clinical trials have shown that the combination of chemotherapy with thermotherapy exhibits strong efficacy. We performed this meta-analysis to evaluate the clinical efficacy and safety of gemcitabine plus cisplatin (GP) and paclitaxel plus cisplatin (TP) combined with thermotherapy in the treatment of NSCLC, as well as to provide reference for clinical practice and future research. METHODS: We searched international (Cochrane Library, PubMed, and EMBASE) and Chinese (CBM, CNKI, VIP and Wanfang) databases for relevant articles and imported other retrievable sources, such as tracing-related references. We also corresponded with other authors to obtain certain inaccessible information. Data from all relevant randomized controlled trials (RCT) were collected to compare GP or TP thermochemotherapy with GP or TP chemotherapy alone. The quality of the included studies was assessed by adequate outcome-based standards and clinical circumstances. The meta-analysis was conducted using RevMan 5.1. RESULTS: Fifteen RCTs involving 952 patients were included in this meta-analysis. The results showed that the thermochemotherapy group had higher rates of improvement in quality of life (OR=3.84, 95%CI: 2.61-5.64), survival at 1 year (HR=1.94, 95%CI: 1.21-3.12), and survival at 2 years (HR=2.05, 95%CI: 1.18-3.58) compared with the chemotherapy group, with the differences between them being significant. However, these groups did not differ in other indicators of treatment effectiveness, such as myelosuppression, alimentary canal reactions, hepatic lesions, and diarrhea. CONCLUSION: Compared with chemotherapy alone, thermochemotherapy can improve survival rates and curative effects, ameliorate symptoms, and enhance the quality of life of patients with advanced NSCLC, and it has an acceptable safety profile. The results of this meta-analysis warrant further investigation with a larger sample size and using a high-quality RCT design. 中国肺癌杂志编辑部 2012-08-20 /pmc/articles/PMC5999956/ /pubmed/22901992 http://dx.doi.org/10.3779/j.issn.1009-3419.2012.08.02 Text en 版权所有©《中国肺癌杂志》编辑部2012 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/ |
spellingShingle | 临床研究 GP或TP化疗联合热疗治疗非小细胞肺癌的系统评价 |
title | GP或TP化疗联合热疗治疗非小细胞肺癌的系统评价 |
title_full | GP或TP化疗联合热疗治疗非小细胞肺癌的系统评价 |
title_fullStr | GP或TP化疗联合热疗治疗非小细胞肺癌的系统评价 |
title_full_unstemmed | GP或TP化疗联合热疗治疗非小细胞肺癌的系统评价 |
title_short | GP或TP化疗联合热疗治疗非小细胞肺癌的系统评价 |
title_sort | gp或tp化疗联合热疗治疗非小细胞肺癌的系统评价 |
topic | 临床研究 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999956/ https://www.ncbi.nlm.nih.gov/pubmed/22901992 http://dx.doi.org/10.3779/j.issn.1009-3419.2012.08.02 |
work_keys_str_mv | AT gphuòtphuàliáoliánhérèliáozhìliáofēixiǎoxìbāofèiáidexìtǒngpíngjià AT gphuòtphuàliáoliánhérèliáozhìliáofēixiǎoxìbāofèiáidexìtǒngpíngjià AT gphuòtphuàliáoliánhérèliáozhìliáofēixiǎoxìbāofèiáidexìtǒngpíngjià AT gphuòtphuàliáoliánhérèliáozhìliáofēixiǎoxìbāofèiáidexìtǒngpíngjià AT gphuòtphuàliáoliánhérèliáozhìliáofēixiǎoxìbāofèiáidexìtǒngpíngjià AT gphuòtphuàliáoliánhérèliáozhìliáofēixiǎoxìbāofèiáidexìtǒngpíngjià |